WO2003006645A3 - Method and composition for inhibiting heparanase activity - Google Patents

Method and composition for inhibiting heparanase activity Download PDF

Info

Publication number
WO2003006645A3
WO2003006645A3 PCT/US2002/021773 US0221773W WO03006645A3 WO 2003006645 A3 WO2003006645 A3 WO 2003006645A3 US 0221773 W US0221773 W US 0221773W WO 03006645 A3 WO03006645 A3 WO 03006645A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogen
heparanase
composition
present
heparanase activity
Prior art date
Application number
PCT/US2002/021773
Other languages
French (fr)
Other versions
WO2003006645A2 (en
Inventor
Peter Bohlen
Daniel Hicklin
Paul Kussie
Yiwen Li
Original Assignee
Imclone Systems Inc
Peter Bohlen
Daniel Hicklin
Paul Kussie
Yiwen Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Peter Bohlen, Daniel Hicklin, Paul Kussie, Yiwen Li filed Critical Imclone Systems Inc
Priority to US10/483,858 priority Critical patent/US20040247577A1/en
Priority to CA002453566A priority patent/CA2453566A1/en
Priority to JP2003512403A priority patent/JP2005521379A/en
Priority to EP02763248A priority patent/EP1417304A4/en
Publication of WO2003006645A2 publication Critical patent/WO2003006645A2/en
Publication of WO2003006645A3 publication Critical patent/WO2003006645A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)

Abstract

The present invention relates to methods of inhibiting heparanase activity and treating various conditions by administering to an animal an effective amount of an immunogen that elicits an immune response to heparanase. According to the present invention, the immunogen is heparanase or a fragment thereof and, preferably, the immunogen is an antigen presenting cell (APC), such as a dendritic cell (DC), displaying heparanase or a fragment thereof on the surface. The present invention also relates to compositions containing the immunogen.
PCT/US2002/021773 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity WO2003006645A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/483,858 US20040247577A1 (en) 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity
CA002453566A CA2453566A1 (en) 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity
JP2003512403A JP2005521379A (en) 2001-07-13 2002-07-10 Methods and compositions for inhibiting heparanase activity
EP02763248A EP1417304A4 (en) 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30544601P 2001-07-13 2001-07-13
US60/305,446 2001-07-13
US35755302P 2002-02-15 2002-02-15
US60/357,553 2002-02-15

Publications (2)

Publication Number Publication Date
WO2003006645A2 WO2003006645A2 (en) 2003-01-23
WO2003006645A3 true WO2003006645A3 (en) 2003-07-24

Family

ID=26974593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021773 WO2003006645A2 (en) 2001-07-13 2002-07-10 Method and composition for inhibiting heparanase activity

Country Status (4)

Country Link
EP (1) EP1417304A4 (en)
JP (1) JP2005521379A (en)
CA (1) CA2453566A1 (en)
WO (1) WO2003006645A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1479764A1 (en) 2003-05-19 2004-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Heparanase-derived peptides for vaccination of tumor patients
ES2251289B1 (en) * 2004-02-27 2007-07-01 Bioiberica, S.A. NEW THERAPEUTIC USE OF A GROUP OF SULFATED POLYSACARIDS.
KR101578342B1 (en) * 2008-03-31 2015-12-16 가부시키가이샤 시세이도 Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method
CA2959624A1 (en) * 2014-09-02 2016-03-10 The Children's Hospital Of Philadelphia Compositions and methods for the inhibition of chondrogenesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242238B1 (en) * 1997-10-28 2001-06-05 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
WO2000052178A1 (en) * 1999-03-01 2000-09-08 Insight Strategy & Marketing Ltd. Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
DE19955803A1 (en) * 1999-11-19 2001-05-23 Knoll Ag Use of heparanase inhibitors for the treatment of cardiac insufficiency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242238B1 (en) * 1997-10-28 2001-06-05 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1417304A4 *

Also Published As

Publication number Publication date
JP2005521379A (en) 2005-07-21
EP1417304A2 (en) 2004-05-12
CA2453566A1 (en) 2003-01-23
EP1417304A4 (en) 2005-11-23
WO2003006645A2 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
IN2006KO01346A (en)
PL331802A1 (en) Substituted cyclic amines as metaloprotease inhibitors
DE69936102D1 (en) USE OF TNF-ALPHA INHIBITORS FOR THE TREATMENT OF NERVE ROOT DAMAGE
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
CA2437844A1 (en) Method for increasing leptin levels using nicotinic acid compounds
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
AU2251901A (en) Methods and compounds for inhibiting MRP1
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
MXPA01003501A (en) Method to mitigate plant stress.
WO2000000198A8 (en) Piperidine derivatives having effects on serotonin related systems
AU9624198A (en) Quinoline and quinazoline derivatives having corticotropin releasing factor (crf) antagonist activity
ES8704482A1 (en) Method of treating liver diseases using pure silibinin
WO2002096420A3 (en) Method for treating nerve injury caused by surgery
WO2004032908A3 (en) Method of inhibiting angiogenesis
WO1993015112A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION
WO2003006645A3 (en) Method and composition for inhibiting heparanase activity
MXPA03008801A (en) Aryl oxime-piperazines useful as ccr5 antagonists.
IL165220A0 (en) Novel compounds, their use and preparation
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO1999057278A3 (en) IMMUNIZATION AGAINST AND TREATMENT FOR INFECTION BY $i(H.PYLORI)
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
EP1028754A4 (en) Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells
WO2004060878A3 (en) Inhibitors of phosphatases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003512403

Country of ref document: JP

Ref document number: 2453566

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002763248

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002763248

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10483858

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002763248

Country of ref document: EP